Treatment of Complicated Vaginal Yeast Infection

Definition and Diagnosis

The Centers for Disease Control and Prevention recommends that complicated vaginal candidiasis includes severe disease, recurrent disease, non-albicans species, or immunocompromised hosts 1, 2, 4
Complicated vaginal candidiasis is defined by presentations such as severe disease with extensive vulvar erythema, edema, excoriation, or fissure formation, recurrent disease with ≥4 episodes per year, non-albicans species, particularly C. glabrata or C. krusei, or immunocompromised hosts, including those with diabetes, HIV, or corticosteroid use 1, 2, 4

For severe acute complicated VVC, the American College of Obstetricians and Gynecologists recommends fluconazole 150 mg orally every 72 hours for 2-3 total doses, or alternatively, topical azole therapy for 7-14 days 1, 3, 4
For recurrent vulvovaginal candidiasis, a two-phase approach is mandatory, starting with induction therapy using fluconazole 150 mg orally, repeated 3 days later, or topical azole therapy for 7-14 days, followed by maintenance therapy with fluconazole 150 mg orally once weekly for 6 months 1, 2, 3, 4
The Centers for Disease Control and Prevention recommends that for non-albicans species, especially C. glabrata, boric acid 600 mg intravaginal gelatin capsule daily for 14 days is first-line therapy 2, 3

In pregnant women, the American College of Obstetricians and Gynecologists recommends avoiding oral fluconazole completely due to association with spontaneous abortion and congenital malformations, and using only topical azole therapy for 7 days 2, 3
For HIV-positive patients, treatment regimens should be identical to HIV-negative women, with expected response rates equivalent regardless of HIV status 1, 2, 3

Before initiating therapy, confirm diagnosis with wet-mount preparation with 10% KOH demonstrating yeast or pseudohyphae, normal vaginal pH (≤4.5), and vaginal culture if microscopy is negative but clinical suspicion remains high, or for recurrent cases to identify non-albicans species 1, 2, 3, 4

The Centers for Disease Control and Prevention recommends not using single-dose therapy for complicated VVC, reserving this only for uncomplicated mild-to-moderate disease, and not treating asymptomatic colonization, as 10-20% of women normally harbor Candida without infection 2, 3

Evaluate patients 1 month after completing induction therapy to verify efficacy before initiating maintenance, and reevaluate only if symptoms persist or recur within 2 months 2, 4

Oral fluconazole may interact with quinidine, erythromycin, pimozide, calcium channel antagonists, warfarin, cyclosporine, protease inhibitors, oral hypoglycemic agents, and phenytoin, and may cause nausea, abdominal pain, and headache 2, 4